The online trading industry has continued to grow rapidly in recent years, especially in Southeast Asia where more retail traders are participating…
Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone1Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options2,3If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR/MSI-H* colon cancer after surgery Basel, 11 June 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY)…
